785 articles
A newly identified trigger in brown fat activates a hidden calorie-burning pathway and may unlock new treatments for bone disease.
Eli Lilly suggests lower doses of tirzepatide may safely sustain weight loss at potentially lower cost, opening new options for long-term obesity management.
Two drug-free approaches — an elemental diet and VR-delivered CBT — showed meaningful IBS symptom relief in new clinical research.
A celebrity endorsement on Joe Rogan's podcast caused ivermectin prescriptions for cancer patients to nearly double, highlighting misinformation risks.
A large U.S. study finds stage IV breast cancer diagnoses rose significantly from 2010–2021, even as survival improved. Drivers remain unclear.
Real-world data from 660 peritoneal dialysis patients shows apixaban rivals warfarin in stroke prevention with comparable bleeding risk.
A new study links GLP-1 agonists to dramatic survival benefits in breast cancer patients, but experts warn the results are likely too good to be true.
New research finds semaglutide and tirzepatide affect muscle mass no differently than ordinary caloric restriction, easing a major concern.
Fractyl Health wins approval for a one-time pancreatic gene therapy that mimics natural GLP-1 signaling in type 2 diabetes patients.
PulseSight's iron-regulating gene therapy slowed geographic atrophy growth in a first-in-human trial, with Phase 2 planned for 2026.
Vasa Therapeutics advances VS-214, a peptide targeting poor limb circulation, toward first human trials in 2026 — addressing a massively underserved condition.
MBX 4291, a once-monthly GLP-1/GIP prodrug, delivered 7% average weight loss in 8 weeks with minimal side effects in Phase 1 data.
